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ic suspenAbstract A new stability-indicating RP-HPLC assay method was developed and validated for
quantitative determination of Levocabastine HCl in bulk drugs and in ophthalmic suspensions in
the presence of degradation products generated from forced degradation studies. The system con-
sisted of Thermo Hypersil CPS column (CN column) (150 mm, 4.6 mm i.d., 5 lm), and the detec-
tion was performed at 210 nm. The mobile phase was a mixture of ethanol–ammonium acetate (pH
3.0; 0.05 M) (40:60, v/v) pumped at 25 C with a ﬂow rate of 1.2 mL/min. The calibration curve was
linear from 50 to 200 lg/mL with R2 > 0.999. The detection limit (DL) and quantitation limit (QL)
were 0.9 and 3 lg/mL, respectively. Accuracy (mean recovery: 100.11%) and precision were found
to be satisfactory. Stress conditions including acid, alkali hydrolysis, water stress, oxidation,
photolysis, and heat were applied. The degradation products did not interfere with the detection
of Levocabastine HCl, thus the method can be considered as a stability indicating method. The
proposed method can be used for quality control assay of Levocabastine HCl in bulk drug and
in ophthalmic suspensions and for the stability studies as a result of the ability of the method to
separate Levocabastine HCl from its degradation products and excipients.
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sions. Arabian Journal of Chemistry (1. Introduction
Levocabastine HCl is chemically (3S, 4R)-1-[cis-4-cyano-4-(4-
ﬂuorophenyl) cyclohexyl]-3-methyl-4-phenylpiperidine-4- car-
boxylic acid monohydrochloride (BP, 2009). (See Fig. 1).
Levocabastine, a piperidine derivative, is a long-acting and
potent antihistamine (Sweetman, 2009). It is an antiallergicier B.V. All rights reserved.
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Figure 1 Structural formula of Levocabastine HCl.
Table 1 Results from system suitability studies.
Property Values Required limits
RSD of peak area 0.241 RSD 6 1% for nP 5
RSD of retention time 0.059 RSD 6 1% for nP 5
Tailing factor (T) 1.48 T< 2
Capacity factor (k0) 2.66 k0 > 2
Theoretical plate (N) 2630 plate N> 2000
2 H. AlAani et al.medication. It inhibits processes in the body that cause allergic
symptoms after exposure to an allergen.
Levocabastine ophthalmic is used to treat ocular (eye)
symptoms of allergic conditions, such as inﬂammation, itch-
ing, watering, and burning (www.rxlist.com/livostin-drug/pa-
tient-images-side-effects.htm, 2013).
Very few methods have been reported for the determina-
tion of Levocabastine HCl in the bulk drug by volumetric
titration (BP, 2009; USP, 2011). Also, very few methods have
been described for the determination of related substances
and organic impurities in the Levocabastine HCl in bulk drug
using the capillary electrophoresis technique (BP, 2009; USP,
2011).
According to Current Good Manufacturing Practices, all
drugs must be tested with a stability-indicating assay method
before release. To date, no stability indicating HPLC assay
method for the determination of Levocabastine HCl isFigure 2 Chromatogram of analyt
Please cite this article in press as: AlAani, H. et al., Development and validation of
HCl in bulk drug and in ophthalmic suspensions. Arabian Journal of Chemistryavailable in the literature. It was felt necessary to develop a
stability-indicating liquid chromatography (LC) method for
the determination of Levocabastine HCl as bulk drug and as
pharmaceutical dosage forms and to separate the drug from
the degradation products under the International Conference
on Harmonization (ICH) suggested conditions (hydrolysis,
oxidations, photolysis and thermal stress) (Bakshi and Singh,
2002; ICH, 2003). Therefore, the principal objective of this
study was to develop a new, simple, economical, precise, and
reproducible stability indicating RP-HPLC method with a
wide linear range and good sensitivity for assay of Levocabas-
tine HCl in the bulk drug and in the pharmaceutical dosage
forms (ophthalmic suspensions).
2. Materials and methods
2.1. Chemicals and solutions
Levocabastine HCl reference substance was purchased from
European Pharmacopoeia (EDQM), batch No. 1.1. Levoc-
abastine HCl bulk drug (purity 99.6%) was obtained from
Yonsung (Korea). Eye drop, (Livostin 0.05%, batch No.
ACB0D00, Johnson & Johnson S.p.A, Italy), was purchased
from the market. Ethanol used was of HPLC grade. All other
reagents used in this study were of AR grade. Puriﬁed water
was used for making the solutions.
2.2. Chromatographic conditions
Separations were performed with a HPLC (LA Chrom ELITE,
VWR Hitachi, Germany, equipped with L-2130 pump, L-2200
auto sampler, L-2300 column oven, and UV photo diode array
detector L-2455). The out-put signal was monitored and pro-
cessed using EZ Chrom ELITE software.
HPLC system used for reproducibility was a Knauer, Ger-
many, equipped with a 1050 pump, 4050 column oven, and UV
photo diode array detector 2850.
The chromatographic column used was Thermo Hypersil
CPS column (CN column) (150 mm, 4.6 mm i.d., 5 lm). Theical reference standard solution.
stability-indicating RP-HPLC method for the determination of Levocabastine
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Figure 3 Chromatogram of placebo solution.
Figure 4 Calibration curve of Levocabastine HCl.
Table 2 Accuracy of the method in the range studied.




Mean recovery = 100.11%
Table 4 Regression line parameters for analytical procedurel.
Linearity parameter Results




Development and validation of stability-indicating RP-HPLC method 3mobile phase comprised of a mixture of ethanol–ammonium
acetate (pH 3.0; 0.05 M) (40:60, v/v). The pH of the ammo-
nium acetate solution was adjusted to 3.0 with orthophos-
phoric acid. Solution of 0.05 M NaOH was used as diluent.
The mobile phase was ﬁltered through 0.45 micron mem-
brane ﬁlter, degassed in ultrasonic bath and pumped from
the respective solvent reservoir to the column at a ﬂow rate
of 1.2 mL/min. The column temperature was maintained at
25 C and the detection wavelength was 210 nm. The injection
volume was 20 lL. The column was equilibrated for 60 min
prior to the injection of the drug solution.
2.3. Preparation of standard solution
25 mg of Levocabastine HCl Reference Standard was accu-
rately weighed, transferred in a 25 mL volumetric ﬂask,Table 3 The precision of the method in the range studied.
Precision Results
Concentration (lg/ml) RSD of peak Area RSD of Retention time
Repeatability 50 1.514 0.064
100 1.470 0.224
200 1.325 0.113
Intermediate precision 50 1.107 0.207
100 1.359 0.066
200 0.868 0.042
Reproducibility 50 1.256 0.149
100 1.258 0.256
200 0.993 0.094
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Figure 5 Chromatogram of standard solution after 1 week.
Table 5 Results of robustness study.
Parameter Variation Observed value
RSD% of area RSD% of R.T Tailing factor (T) Capacity factor (k0) Theoretical plate (N)
Flow rate 1 mL/min 0.948 0.562 1.48 2.70 2982
1.4 mL/min 0.431 0.079 1.46 2.47 2474
Injection volume 10 lL 0.624 0.056 1.44 2.58 2731
30 lL 0.282 0.046 1.51 2.62 2403
M. Phase composition 45% ethanol 0.784 0.072 1.43 2.08 2344
35% ethanol 0.698 0.855 1.58 4.01 2539
pH of M. Phase 2.8 0.814 0.066 1.49 2.84 2684
3.2 0.466 0.103 1.43 2.23 2644
Column temperature 20 C 0.596 0.062 1.54 2.72 2501
30 C 0.406 0.372 1.47 2.15 2377
Wave length 205 nm 0.729 0.069 1.49 2.66 2506
215 nm 0.549 0.066 1.48 2.69 2579
4 H. AlAani et al.dissolved and diluted to 25 mL with the diluent. From this
stock solution, 1 mL was transferred in a 10 mL volumetric
ﬂask and diluted with the diluent. This ﬁnal solution contained
100 lg/mL of Levocabastine HCl.
2.4. Preparation of sample solution
The commercially available eye drop contains 0.05%
suspension of Levocabastine (0.5 mg/mL), as Levocabastine
HCl. From this well shaken eye drop, 2 mL suspension was
carefully transferred in a 10 mL volumetric ﬂask containing
about 4 mL of the diluent and sonicated for 5 min to obtainTable 6 Result of Levocabastine HCl in marketed product.
Marketed formulation Labeled amo
Livostin 0.05% 0.5
Local eye drop 0.5
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HCl in bulk drug and in ophthalmic suspensions. Arabian Journal of Chemistrya clear solution. Then the solution was diluted to volume with
the same diluent. A sample was ﬁltered using a 0.45 lm nylon
syringe ﬁlter. The concentration obtained was 100 lg/mL of
Levocabastine.
2.5. Calculation
The quantity of Levocabastine (as percentage) in the eye drop
was calculated by the following formula:
ðAU=ASÞ  ðMr1=Mr2Þ  P ð1Þ
In whichunt (mg/mL) Amount found %
101.17
99.62
stability-indicating RP-HPLC method for the determination of Levocabastine
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Table 7 Results from analysis of samples by the forced degradation study.
Stress conditions Time (h) Assay of active substance (%) Peak puritya
Water stress/80 C 3 98.57 1.000
3 M HCl/80 C/20 mL 3 99.89 (No degradation) 1.000
3 M NaOH/80 C/20 mL 3 8.48 1.000
3 M NaOH/80 C/10 mL 3 11.05 0.998
3 M NaOH/80 C/5 mL 3 31.14 1.000
3 M NaOH/80 C/3 mL 3 45.71 0.999
30% H2O2/80 C/20 mL 3 (Full degradation) –
30% H2O2/80 C/5 mL 3 (Full degradation) –
30% H2O2/80 C/2 mL 3 Below quantitation limit –
30% H2O2/80 C/1 mL 3 Below quantitation limit –
3% H2O2/80 C/5 mL 3 5.43 0.991
3% H2O2/80 C/2 mL 3 25.90 1.000
Thermal/80 C 1 week 25.62 1.000
Photo degradation/white light 1 week 98.35 1.000
a Peak purity values >0.990 indicate the homogenous peak (Panchal and Suhagia, 2011).
Figure 6 Chromatogram of water stress degradation of Levocabastine HCl.
Development and validation of stability-indicating RP-HPLC method 5 AU peak response from the sample solution
 AS peak response from the standard solution
 Mr1 molecular weight of Levocabastine, 420.52
 Mr2 molecular weight of Levocabastine HCl, 457.00
 P potency of reference standard (as percentage).
2.6. Method validation
The proposed RP-HPLC method was validated as per ICH
guidelines (ICH, Q2A, 1995; ICH, Q2B, 1996; ICH, Q2
(R1), 1995).
2.7. Procedure for forced degradation study
2.7.1. Diluent
Solution of 0.05 M NaOH.
2.7.2. Stock solution
200 mg of Levocabastine HCl was accurately weighed, trans-
ferred in a 200 mL volumetric ﬂask, dissolved and diluted toPlease cite this article in press as: AlAani, H. et al., Development and validation of
HCl in bulk drug and in ophthalmic suspensions. Arabian Journal of Chemistry (200 mL with the diluent. This solution contained 1 mg/mL of
Levocabastine HCl.
2.7.3. Water stress degradation
20 mL of water was added to 10 mL of stock solution and was
kept at 80 C for about 3 h in water bath; the solution was al-
lowed to attend ambient temperature. Then volume was made
up to 100 mL with the diluent to achieve ﬁnal concentration of
100 lg/mL.
2.7.4. Acidic degradation
20 mL of 3 M HCl was added to 10 mL of stock solution and
was kept at 80 C for about 3 h in water bath; the solution was
allowed to attend ambient temperature. Then solution was
neutralized by 20 mL of 3 M NaOH and volume was made
up to 100 mL with the diluent to achieve ﬁnal concentration
of 100 lg/mL.
2.7.5. Alkali degradation
3,5,10, and 20 mL of 3 M NaOH were added to four contain-
ers, each contained 10 mL of stock solution and were kept atstability-indicating RP-HPLC method for the determination of Levocabastine
2013), http://dx.doi.org/10.1016/j.arabjc.2013.11.051
Figure 7 Chromatogram of Acidic degradation of Levocabastine HCl.
Figure 8 Chromatogram of Alkali degradation of Levocabastine HCl (3 M NaOH/80 C/20 mL).
6 H. AlAani et al.80 C for about 3 h in water bath, the solutions were allowed
to attend ambient temperature. Then solutions were neutral-
ized by sufﬁcient amount of 3 M HCl (3, 5, 10, and 20 mL)
and volume was made up to 100 mL with the diluent to achieve
ﬁnal concentration of 100 lg/mL.
2.7.6. Oxidative degradation
2 and 5 ml of 3% H2O2 and 1,2,5, and 20 mL of 30% H2O2
were added to six containers, each contained 10 mL of stock
solution and were kept at 80 C about 3 h in water bath, the
solutions were allowed to attend ambient temperature. Then
volume was made up to 100 mL with the diluent to achieve ﬁ-
nal concentration of 100 lg/mL.
2.7.7. Thermal degradation
10 mL of stock solution was kept at 80 C for one week. The
solution was allowed to attend ambient temperature. Then vol-
ume was made up to 100 mL with the diluent to achieve ﬁnal
concentration of 100 lg/mL.Please cite this article in press as: AlAani, H. et al., Development and validation of
HCl in bulk drug and in ophthalmic suspensions. Arabian Journal of Chemistry2.7.8. Photodegradation
10 mL of stock solution was exposed to white light for one
week. Then volume was made up to 100 mL with the diluent
to achieve ﬁnal concentration of 100 lg/mL.
2.8. Note
Solutions for water stress, acidic, alkali, oxidative, and thermal
degradation were kept in the dark in order to avoid the possi-
ble effect of light.3. Results and discussion
3.1. System suitability
System suitability is the checking of a system to ensure system
performance before or during the analysis of unknowns.
System suitability tests are an integral part of methodstability-indicating RP-HPLC method for the determination of Levocabastine
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.11.051
Figure 9 Chromatogram of Alkali degradation of Levocabastine HCl (3 M NaOH/80 C/10 mL).
Figure 10 Chromatogram of Alkali degradation of Levocabastine HCl (3 M NaOH/80 C/5 mL).
Figure 11 Chromatogram of Alkali degradation of Levocabastine HCl (3 M NaOH/80 C/3 mL).
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8 H. AlAani et al.development and are performed to evaluate the behavior of the
chromatographic system. Capacity factor (k0), plate number
(N), tailing factor (T), and RSD were evaluated for ﬁve repli-
cate injections of the drug at a concentration of 100 lg/mL.




Speciﬁcity is the ability to assess unequivocally the analyte in
the presence of components which may be expected to be
present. Typically these might include impurities, degradants,
and matrix components (USP, 2007, General chapter
<1225>).
It was clear that no peak was observed in the chromato-
gram of placebo solution at the retention time of Levocabas-
tine HCl. (Figs. 2 and 3).
Also, degradation studies showed that the degradation
products did not interfere with the detection of Levocabastine
HCl. The peak purity spectra of Levocabastine HCl were re-
corded using a PDA detector. Peak purities from sample solu-
tions were >0.990. Peak purity >0.990 indicates method
speciﬁcity (Panchal and Suhagia, 2011).
3.2.2. Accuracy
To study the reliability, the suitability, and the accuracy of the
method, recovery experiments were carried out. Known quan-
tities of the pure drug were added to the placebo to make sam-
ples at the levels of 50%, 100%, and 200%, and were assayed
by the proposed method. Accuracy was calculated as the per-
centage of recovery and the results are shown in Table 2.
3.2.3. Precision
The precision was demonstrated at three levels: repeatability,
intermediate precision, and reproducibility (between laborato-
ries’ precision). Each level of precision was investigated by 3
sequential replicate of injections of three concentrations of
50, 100 and 200 lg/mL. The precision was expressed as relativeFigure 12 Chromatogram of oxidative degradation
Please cite this article in press as: AlAani, H. et al., Development and validation of
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results of three levels of precision are shown in Table 3.
3.2.4. Detection limit (DL) and quantitation limit (QL)
Ratios of 3:1 and 10:1 signal-to-noise were considered
acceptable for estimation of the DL and QL, respectively
(Ravichandran et al., 2010). So, the limit of detection and
the limit of quantitation were determined to be 0.9 and 3 lg/
mL, respectively.
3.2.5. Linearity and range
The linearity of measurement was evaluated by analyzing dif-
ferent concentrations of the standard solutions of the Levoc-
abastine HCl. Calibration curve was constructed by plotting
average peak area against concentration and then the regres-
sion equation was computed. The summary of linearity param-
eters is shown in Table 4 and Fig. 4. As demonstrated in Fig. 4,
the calibration curve covers concentrations of 50% to 200% of
the test concentration (50 to 200 lg/mL).
3.2.6. Ruggedness and robustness
The ruggedness or the degree of reproducibility of the test re-
sults in different laboratories was demonstrated by the analysis
of the same sample under different conditions of laboratories,
analysts, instruments, lots of columns and time.
The robustness of the analytical procedure which is the
measure of method’s capacity to remain unaffected by small,
but deliberate, variations in method parameters is shown in
this study. Robustness (Table 5) was performed in 100% test
concentration (100 lg/mL) and was explored using mobile
phase composition, mobile phase pH, ﬂow rate, column tem-
perature, wave length, and injection volume.
3.3. Mobile phase stability
The stability of the mobile phase was evaluated, so the mobile
phase was stored at 4–8 C for 1 week. The aged mobile phase
was compared using a freshly prepared one. The mobile phase
was stable up to 1 week at 4–8 C.of Levocabastine HCl (30% H2O2/80 C/5 mL).
stability-indicating RP-HPLC method for the determination of Levocabastine
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Figure 13 Chromatogram of oxidative degradation of Levocabastine HCl (30% H2O2/80 C/2 mL).
Figure 14 Chromatogram of oxidative degradation of Levocabastine HCl (30% H2O2/80 C/1 mL).
Figure 15 Chromatogram of oxidative degradation of Levocabastine HCl (3% H2O2/80 C/5 mL).
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Figure 17 Chromatogram of thermal degradation of Levocabastine HCl.
Figure 18 Chromatogram of photodegradation of Levocabastine HCl.
Figure 16 Chromatogram of oxidative degradation of Levocabastine HCl (3% H2O2/80 C/2 mL).
10 H. AlAani et al.
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The stability of the standard solution was tested at intervals of
24, 48 h and 1 week at ambient temperature. There were no
signiﬁcant changes in the peak area, retention time, and sym-
metry of the peak of Levocabastine HCl after 48 h. These re-
sults indicate that the standard solution was stable for 48 h
at ambient temperature. After one week, about 1% change
of peak area of Levocabastine HCl was obtained, and degrada-
tion was observed. Fig. 5 shows the chromatogram of standard
solution after 1 week.
3.5. Analysis of marketed products
The validated method was applied for the analysis of Levoc-
abastine eye drops from two different manufacturers. In both
cases assay obtained was more than 99%. Results are summa-
rized in Table 6.
3.6. Result of forced degradation experiments
When stress conditions were applied to Levocabastine HCl,
the HPLC results showed that there was no interference be-
tween the tested drug and the degradation products. Peak pur-
ity results greater than 0.990 indicate that the Levocabastine
HCl peak is homogeneous in all stress conditions tested thus
establishing the speciﬁcity and conﬁrming the stability indicat-
ing power of the assay method. Table 7 indicates the extent of
degradation, peak purity and assay of Levocabastine HCl un-
der various stress conditions. It was observed that the drug
showed extensive degradation in oxidative condition, alkali
hydrolysis, and thermal. Figs. 6–18 show the chromatograms
obtained after degradation under different stress conditions.
4. Conclusion
The present developed method is sensitive, rapid, robust,
precise and accurate. Application of this method for the anal-
ysis of eye drops shows that neither the degradation products
nor the excipients, interfere with the analytical determination.
This indicates that the proposed method could be used as aPlease cite this article in press as: AlAani, H. et al., Development and validation of
HCl in bulk drug and in ophthalmic suspensions. Arabian Journal of Chemistry (stability-indicating method for the determination of Levoc-
abastine HCl either in bulk powder or in pharmaceutical for-
mulations (ophthalmic suspensions).Acknowledgements
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